Korean J Urol.  2011 Sep;52(9):603-606.

The Clinical Usefulness of Nuclear Matrix Protein-22 in Patients with Atypical Urine Cytology

• Ahn JS
• Kim HS
• Chang SG
• Jeon SH

Abstract

PURPOSE
Difficulty exists in interpreting the significance of atypical urine cytology. This study was performed to assess the diagnostic utility of nuclear matrix protein-22 (NMP-22) testing when atypical cells are detected during urine cytology.
MATERIALS AND METHODS
Among patients whose urine cytology was reported as atypical between January 2004 and December 2009, a total of 275 who also underwent NMP-22 testing were enrolled in the present study. These patients were further divided into the screening group (143 patients examined as outpatients for hematuria) and the follow-up group (132 patients followed up for previously diagnosed bladder cancer). The sensitivity, specificity, positive and negative predictive values, and accuracy were assessed for atypical cytology alone and in conjunction with NMP-22.
RESULTS
Of the 275 patients exhibiting atypical urine cytology, cancer was confirmed in 85, yielding a positive predictive value of 30.9% (85/275). Of the 96 patients testing positive for NMP-22, 58 were diagnosed with bladder cancer. The positive predictive value in conjunction with NMP-22 was 60.4% (58/96). The sensitivity, specificity, negative predictive value, and accuracy were 68.2% (58/85), 80.0% (152/190), 84.9% (152/179), and 76.2% (210/275), respectively. Testing for NMP-22 in the screening and follow-up groups increased the positive predictive value from 30.0% (43/143) to 64.0% (32/50) and from 31.3% (42/132) to 56.5% (26/46), respectively; there was no significant difference between the screening and follow-up groups (p=0.106).
CONCLUSIONS
When only cases with atypical urine cytology were examined, NMP-22 testing increased the detection rate of bladder cancer regardless of whether the test was used in screening hematuria or in following up patients.

Keyword

Cytology; Nuclear matrix; Urinary bladder neoplasms

MeSH Terms

Follow-Up Studies
Hematuria
Humans
Mass Screening
Nuclear Matrix
Outpatients
Sensitivity and Specificity
Urinary Bladder
Urinary Bladder Neoplasms

Reference

1. Farrow GM. Pathologist's role in bladder cancer. Semin Oncol. 1979. 6:198–206.

2. Melamed MR, Koss LG. Developments in cytological diagnosis of cancer. Med Clin North Am. 1966. 50:651–666.

3. Jo MK, Chung JS, Lee SE. The significance of atypical cell in urinary cytology. Korean J Urol. 1998. 39:9–14.

4. Farrow GM. Pathologist's role in bladder cancer. Semin Oncol. 1979. 6:198–206.

5. Melamed MR, Koss LG. Developments in cytological diagnosis of cancer. Med Clin North Am. 1966. 50:651–666.

6. Raina R, Pahlajani G, Ponsky LE, Agarwal A, Zippe CD. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22. BJU Int. 2008. 102:297–300.

7. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol. 2001. 166:75–78.

8. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 1999. 162:53–57.

9. Gupta NP, Sharma N, Kumar R. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology. 2009. 73:592–596.

10. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000. 163:524–527.

11. Nabi G, Greene DR, O'Donnell M. How important is urinary cytology in the diagnosis of urological malignancies? Eur Urol. 2003. 43:632–636.

12. Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol. 1997. 31:163–168.

13. Deshpande V, McKee GT. Analysis of atypical urine cytology in a tertiary care center. Cancer. 2005. 105:468–475.

14. Brown FM. Urine cytology. It is still the gold standard for screening? Urol Clin North Am. 2000. 27:25–37.

15. Feifer AH, Steinberg J, Tanguay S, Aprikian AG, Brimo F, Kassouf W. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. Urology. 2010. 75:1278–1282.

16. Kapila K, Kehinde EO, Anim JT, Mojiminiyi OA, Vinsu A, George SS, et al. Could nuclear matrix 22(NMP22) play a role with urine cytology in screening for bladder cancer? experience at Kuwait University. Cytopathology. 2008. 19:369–374.

17. Choi HS, Lee SI, Kim DJ, Jeong TY. Usefulness of the NMP22BladderCheck test for screening and follow-up of bladder cancer. Korean J Urol. 2010. 51:88–93.

18. Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 2006. 97:997–1001.